Fernando Botto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fernando Botto has a total of 626 co-authors. Here are the top co-authors by number of shared publications:
- Philip James Devereaux
Population Health Research Institute, McMaster University, Hamilton, ON, Canada
9 shared publications - Reitze Nils Rodseth
First Do No Harm Southern Africa, Cape Town, South Africa; and, Department of Anaesthesiology, School of Clinical Medicine, University of KwaZulu-Natal, Pietermaritzburg, South Africa
8 shared publications Alben Sigamani
7 shared publicationsOtavio Berwanger
Instituto de Ensino e Pesquisa do Hospital do Coração (IEP-HCor), São Paulo, Brazil
7 shared publications- Pablo Alonso-Coello
Centre for Biomedical Research in Epidemiology and Public Health (CIBERESP) Madrid Spain
7 shared publications Shirley Pettit
Population Health Research Institute, Hamilton, ON, Canada
7 shared publications
Latest Publications
- 26 June 2026
- Published by Elsevier in Current Problems in Cardiology
- Vol. 51 (10) , 103394
Atherosclerosis as an evolutionary mismatch disease: from ancestral biology to cardiometabolic vulnerability
- 26 June 2026
- Published by Elsevier in Current Problems in Cardiology
- Vol. 51 (10) , 103394
Atherosclerosis as an evolutionary mismatch disease: from ancestral biology to cardiometabolic vulnerability
- 6 September 2024
- Published by Elsevier in Atherosclerosis
- Vol. 398, 118594
Is colchicine on its way to a place in the polypill for cardiovascular prevention?
- 6 September 2024
- Published by Elsevier in Atherosclerosis
- Vol. 398, 118594
Is colchicine on its way to a place in the polypill for cardiovascular prevention?
- Open Access
- 26 July 2024
- Published by Revista Argentina de Cardiologia in Revista Argentina de Cardiologia
Impacto de un modelo asistencial específicamente diseñado en el programa de angioplastia coronaria ambulatoria
Background: An outpatient model of care for percutaneous coronary procedures called Radial Lounge (RL) was designed at our center. Patients wear their own clothes throughout their stay, with no mobility restrictions and without fasting. Before and after the procedure, they remain in an armchair accompanied by a family member until discharge, without continuous monitoring, under the supervision of a nurse dedicated exclusively to this area. Objectives: The aim of this study was to evaluate the safety and efficacy of the RL model of care, the same-day discharge (SDD) rate, patient experience, and major adverse cardiovascular events (MACE): in-hospital mortality, overall mortality, and re-hospitalization at 30 days Methods: A retrospective observational cohort study was conducted at a cardiovascular center, including consecutively enrolled patients undergoing elective percutaneous coronary intervention (PCI) in the RL. Results: A total of 2102 elective PCI procedures were included under the RL model. The SDD rate was 85.3% in the first year of its implementation (2018) and reached 89% in 2022. Assessing patient experience, the average score obtained through the Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey was 9.61/10. The rate of MACE was not higher than that reported in the literature. Conclusion: The PCI program in the RL proved to be a safe and effective model in our experience. How to cite this article: Liberman F, Botto FO, Benzadón MN, Lamelas PM, Spaletra PM, Pedernera GO, y cols. Impact of a Specifically Designed Model of Care in an Outpatient Coronary Angioplasty Program. Rev Argent Cardiol 2024;92:183-8. http://dx.doi.org/10.7775/rac.v92.i3.20770
- 26 July 2024
- Published by Revista Argentina de Cardiologia in Revista Argentina de Cardiologia
Open AccessImpacto de un modelo asistencial específicamente diseñado en el programa de angioplastia coronaria ambulatoria
Background: An outpatient model of care for percutaneous coronary procedures called Radial Lounge (RL) was designed at our center. Patients wear their own clothes throughout their stay, with no mobility restrictions and without fasting. Before and after the procedure, they remain in an armchair accompanied by a family member until discharge, without continuous monitoring, under the supervision of a nurse dedicated exclusively to this area. Objectives: The aim of this study was to evaluate the safety and efficacy of the RL model of care, the same-day discharge (SDD) rate, patient experience, and major adverse cardiovascular events (MACE): in-hospital mortality, overall mortality, and re-hospitalization at 30 days Methods: A retrospective observational cohort study was conducted at a cardiovascular center, including consecutively enrolled patients undergoing elective percutaneous coronary intervention (PCI) in the RL. Results: A total of 2102 elective PCI procedures were included under the RL model. The SDD rate was 85.3% in the first year of its implementation (2018) and reached 89% in 2022. Assessing patient experience, the average score obtained through the Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey was 9.61/10. The rate of MACE was not higher than that reported in the literature. Conclusion: The PCI program in the RL proved to be a safe and effective model in our experience. How to cite this article: Liberman F, Botto FO, Benzadón MN, Lamelas PM, Spaletra PM, Pedernera GO, y cols. Impact of a Specifically Designed Model of Care in an Outpatient Coronary Angioplasty Program. Rev Argent Cardiol 2024;92:183-8. http://dx.doi.org/10.7775/rac.v92.i3.20770
- 4 March 2024
- Published by Springer Nature in High Blood Pressure & Cardiovascular Prevention
- Vol. 31 (2) , 177-187
Prevalence and Burden of Carotid and Femoral Atherosclerosis in Subjects Without Known Cardiovascular Disease in a Large Community Hospital in South-America
Introduction Clinical guidelines recommend measurement of arterial (carotid and femoral) plaque burden by vascular ultrasound (VUS) as a risk modifier in individuals at low or moderate risk without known atherosclerotic cardiovascular disease (ASCVD). Aim To evaluate the prevalence of carotid and femoral plaques by age and sex, the burden of subclinical atherosclerosis (SA), and its association with classic CVRF in subjects over 30 years of age without ASCVD. Methods We prospectively enrolled 5775 consecutive subjects referred for cardiovascular evaluation and determined the prevalence and burden of SA using 2D-VUS in carotid and femoral arteries. Results Sixty-one percent were men with a mean age of 51.3 (SD 10.6) years. Overall, plaque prevalence was 51% in carotid arteries, 39.3% in femoral arteries, 62.4% in carotid or femoral arteries, and 37.6% in neither. The prevalence of plaques and SA burden showed an increasing trend with age, being higher in men than in women and starting before the age of 40, both in the carotid and femoral sites. There was also an increasing prevalence of plaques according to the number of CVRF, and interestingly we found a high prevalence of plaques in subjects with 0 or 1 classic CVRF. Conclusions We observed an increased prevalence and burden of carotid or femoral SA, higher in men, beginning before the fourth decade of life and increasing with age. Despite a significant association with classic CVRF, a significant number of subjects with low CVRF were diagnosed with SA.
- 4 March 2024
- Published by Springer Nature in High Blood Pressure & Cardiovascular Prevention
- Vol. 31 (2) , 177-187
Prevalence and Burden of Carotid and Femoral Atherosclerosis in Subjects Without Known Cardiovascular Disease in a Large Community Hospital in South-America
Introduction Clinical guidelines recommend measurement of arterial (carotid and femoral) plaque burden by vascular ultrasound (VUS) as a risk modifier in individuals at low or moderate risk without known atherosclerotic cardiovascular disease (ASCVD). Aim To evaluate the prevalence of carotid and femoral plaques by age and sex, the burden of subclinical atherosclerosis (SA), and its association with classic CVRF in subjects over 30 years of age without ASCVD. Methods We prospectively enrolled 5775 consecutive subjects referred for cardiovascular evaluation and determined the prevalence and burden of SA using 2D-VUS in carotid and femoral arteries. Results Sixty-one percent were men with a mean age of 51.3 (SD 10.6) years. Overall, plaque prevalence was 51% in carotid arteries, 39.3% in femoral arteries, 62.4% in carotid or femoral arteries, and 37.6% in neither. The prevalence of plaques and SA burden showed an increasing trend with age, being higher in men than in women and starting before the age of 40, both in the carotid and femoral sites. There was also an increasing prevalence of plaques according to the number of CVRF, and interestingly we found a high prevalence of plaques in subjects with 0 or 1 classic CVRF. Conclusions We observed an increased prevalence and burden of carotid or femoral SA, higher in men, beginning before the fourth decade of life and increasing with age. Despite a significant association with classic CVRF, a significant number of subjects with low CVRF were diagnosed with SA.
- 3 November 2023
- Published by Elsevier in Public Health
- Vol. 225, 127-132
Gender differences in workplace violence against physicians and nurses in Latin America: a survey from the Interamerican Society of Cardiology
- 3 November 2023
- Published by Elsevier in Public Health
- Vol. 225, 127-132
Gender differences in workplace violence against physicians and nurses in Latin America: a survey from the Interamerican Society of Cardiology
- Open Access
- 25 August 2023
- Published by Revista Argentina de Cardiologia in Revista Argentina de Cardiologia
Impacto de un Heart Team en pacientes con estenosis aórtica candidatos a reemplazo percutáneo.
As transcatheter aortic valve implantation (TAVI) for aortic stenosis (AS) became widespread, there arose the need for a Heart Team (HT) to choose the best treatment. There are few reports as regards its usefulness. Objectives: To analyze treatment outcomes in patients with AS evaluated by a HT for 10 years. Methods: Consecutive enrollment of all patients with AS who were candidates for TAVI between January 2012 and July 2021 to choose the best treatment, including surgical aortic valve replacement (SAVR) and conservative medical management (CMM). Results: Out of 841 patients, 455 were assigned to TAVI (53%), 213 to SAVR (24%), and 183 to CMM (23%). The percentage assigned to TAVI has increased from 48% to 62% over time (p <0.05). Patients who underwent TAVI versus those who underwent SAVR were older (86 ± 7 vs. 83 ± 7 years), had a higher EUROSCORE II (6.2, 95% CI 5.7-6.6 vs. 5.6; 95% CI 4.4-6.5) and were frailer (1.62 ± 1 vs. 0.91 ± 1) in all cases (p <0.01). Actuarial survival (95% CI) at 1 and 2 years was 88% (84-91%) and 82% (77-86%) for TAVI, 83% (76-88%) and 78% (70-84%) for SAVR, and 70% (60-87%) and 59% (48-68%) for CMM, respectively (p <0.001). Conclusions: For the first 10 years after a Heart Team was established for AS decision-making, approximately half of the patients were assigned to TAVI, and the rest were equally assigned in halves to either surgery or observation. Survival for patients who received interventions was similar at 2 years and higher than in those who did not. How to cite this article: Trivi MS, Castro MF, Trossero R, Cura FA, Piccinini FF, Candiello F, y cols. Impact of a Heart Team in patients with aortic stenosis who are candidates for transcatheter aortic valve replacement. Rev Argent Cardiol 2023;91:246-51. http://dx.doi.org/10.7775/rac.v91.i4.20649
- 25 August 2023
- Published by Revista Argentina de Cardiologia in Revista Argentina de Cardiologia
Open AccessImpacto de un Heart Team en pacientes con estenosis aórtica candidatos a reemplazo percutáneo.
As transcatheter aortic valve implantation (TAVI) for aortic stenosis (AS) became widespread, there arose the need for a Heart Team (HT) to choose the best treatment. There are few reports as regards its usefulness. Objectives: To analyze treatment outcomes in patients with AS evaluated by a HT for 10 years. Methods: Consecutive enrollment of all patients with AS who were candidates for TAVI between January 2012 and July 2021 to choose the best treatment, including surgical aortic valve replacement (SAVR) and conservative medical management (CMM). Results: Out of 841 patients, 455 were assigned to TAVI (53%), 213 to SAVR (24%), and 183 to CMM (23%). The percentage assigned to TAVI has increased from 48% to 62% over time (p <0.05). Patients who underwent TAVI versus those who underwent SAVR were older (86 ± 7 vs. 83 ± 7 years), had a higher EUROSCORE II (6.2, 95% CI 5.7-6.6 vs. 5.6; 95% CI 4.4-6.5) and were frailer (1.62 ± 1 vs. 0.91 ± 1) in all cases (p <0.01). Actuarial survival (95% CI) at 1 and 2 years was 88% (84-91%) and 82% (77-86%) for TAVI, 83% (76-88%) and 78% (70-84%) for SAVR, and 70% (60-87%) and 59% (48-68%) for CMM, respectively (p <0.001). Conclusions: For the first 10 years after a Heart Team was established for AS decision-making, approximately half of the patients were assigned to TAVI, and the rest were equally assigned in halves to either surgery or observation. Survival for patients who received interventions was similar at 2 years and higher than in those who did not. How to cite this article: Trivi MS, Castro MF, Trossero R, Cura FA, Piccinini FF, Candiello F, y cols. Impact of a Heart Team in patients with aortic stenosis who are candidates for transcatheter aortic valve replacement. Rev Argent Cardiol 2023;91:246-51. http://dx.doi.org/10.7775/rac.v91.i4.20649
- Open Access
- 25 August 2023
- Published by Revista Argentina de Cardiologia in Revista Argentina de Cardiologia
Impacto de un Heart Team en pacientes con estenosis aórtica candidatos a reemplazo percutáneo.
As transcatheter aortic valve implantation (TAVI) for aortic stenosis (AS) became widespread, there arose the need for a Heart Team (HT) to choose the best treatment. There are few reports as regards its usefulness. Objectives: To analyze treatment outcomes in patients with AS evaluated by a HT for 10 years. Methods: Consecutive enrollment of all patients with AS who were candidates for TAVI between January 2012 and July 2021 to choose the best treatment, including surgical aortic valve replacement (SAVR) and conservative medical management (CMM). Results: Out of 841 patients, 455 were assigned to TAVI (53%), 213 to SAVR (24%), and 183 to CMM (23%). The percentage assigned to TAVI has increased from 48% to 62% over time (p <0.05). Patients who underwent TAVI versus those who underwent SAVR were older (86 ± 7 vs. 83 ± 7 years), had a higher EUROSCORE II (6.2, 95% CI 5.7-6.6 vs. 5.6; 95% CI 4.4-6.5) and were frailer (1.62 ± 1 vs. 0.91 ± 1) in all cases (p <0.01). Actuarial survival (95% CI) at 1 and 2 years was 88% (84-91%) and 82% (77-86%) for TAVI, 83% (76-88%) and 78% (70-84%) for SAVR, and 70% (60-87%) and 59% (48-68%) for CMM, respectively (p <0.001). Conclusions: For the first 10 years after a Heart Team was established for AS decision-making, approximately half of the patients were assigned to TAVI, and the rest were equally assigned in halves to either surgery or observation. Survival for patients who received interventions was similar at 2 years and higher than in those who did not. How to cite this article: Trivi MS, Castro MF, Trossero R, Cura FA, Piccinini FF, Candiello F, y cols. Impact of a Heart Team in patients with aortic stenosis who are candidates for transcatheter aortic valve replacement. Rev Argent Cardiol 2023;91:246-51. http://dx.doi.org/10.7775/rac.v91.i4.20649
- 25 August 2023
- Published by Revista Argentina de Cardiologia in Revista Argentina de Cardiologia
Open AccessImpacto de un Heart Team en pacientes con estenosis aórtica candidatos a reemplazo percutáneo.
As transcatheter aortic valve implantation (TAVI) for aortic stenosis (AS) became widespread, there arose the need for a Heart Team (HT) to choose the best treatment. There are few reports as regards its usefulness. Objectives: To analyze treatment outcomes in patients with AS evaluated by a HT for 10 years. Methods: Consecutive enrollment of all patients with AS who were candidates for TAVI between January 2012 and July 2021 to choose the best treatment, including surgical aortic valve replacement (SAVR) and conservative medical management (CMM). Results: Out of 841 patients, 455 were assigned to TAVI (53%), 213 to SAVR (24%), and 183 to CMM (23%). The percentage assigned to TAVI has increased from 48% to 62% over time (p <0.05). Patients who underwent TAVI versus those who underwent SAVR were older (86 ± 7 vs. 83 ± 7 years), had a higher EUROSCORE II (6.2, 95% CI 5.7-6.6 vs. 5.6; 95% CI 4.4-6.5) and were frailer (1.62 ± 1 vs. 0.91 ± 1) in all cases (p <0.01). Actuarial survival (95% CI) at 1 and 2 years was 88% (84-91%) and 82% (77-86%) for TAVI, 83% (76-88%) and 78% (70-84%) for SAVR, and 70% (60-87%) and 59% (48-68%) for CMM, respectively (p <0.001). Conclusions: For the first 10 years after a Heart Team was established for AS decision-making, approximately half of the patients were assigned to TAVI, and the rest were equally assigned in halves to either surgery or observation. Survival for patients who received interventions was similar at 2 years and higher than in those who did not. How to cite this article: Trivi MS, Castro MF, Trossero R, Cura FA, Piccinini FF, Candiello F, y cols. Impact of a Heart Team in patients with aortic stenosis who are candidates for transcatheter aortic valve replacement. Rev Argent Cardiol 2023;91:246-51. http://dx.doi.org/10.7775/rac.v91.i4.20649
- 1 August 2023
- Published by Revista Argentina de Cardiologia
- Vol. 91 (4) , 246-251
Impact of a Heart Team in patients with aortic stenosis who are candidates for transcatheter aortic valve replacement
As transcatheter aortic valve implantation (TAVI) for aortic stenosis (AS) became widespread, there arose the need for a Heart Team (HT) to choose the best treatment. There are few reports as regards its usefulness. Objectives: To analyze treatment outcomes in patients with AS evaluated by a HT for 10 years. Methods: Consecutive enrollment of all patients with AS who were candidates for TAVI between January 2012 and July 2021 to choose the best treatment, including surgical aortic valve replacement (SAVR) and conservative medical management (CMM). Results: Out of 841 patients, 455 were assigned to TAVI (53%), 213 to SAVR (24%), and 183 to CMM (23%). The percentage assigned to TAVI has increased from 48% to 62% over time (p <0.05). Patients who underwent TAVI versus those who underwent SAVR were older (86 ± 7 vs. 83 ± 7 years), had a higher EUROSCORE II (6.2, 95% CI 5.7-6.6 vs. 5.6; 95% CI 4.4-6.5) and were frailer (1.62 ± 1 vs. 0.91 ± 1) in all cases (p <0.01). Actuarial survival (95% CI) at 1 and 2 years was 88% (84-91%) and 82% (77-86%) for TAVI, 83% (76-88%) and 78% (70-84%) for SAVR, and 70% (60-87%) and 59% (48-68%) for CMM, respectively (p <0.001). Conclusions: For the first 10 years after a Heart Team was established for AS decision-making, approximately half of the patients were assigned to TAVI, and the rest were equally assigned in halves to either surgery or observation. Survival for patients who received interventions was similar at 2 years and higher than in those who did not.
- 1 August 2023
- Published by Revista Argentina de Cardiologia
- Vol. 91 (4) , 246-251
Impact of a Heart Team in patients with aortic stenosis who are candidates for transcatheter aortic valve replacement
As transcatheter aortic valve implantation (TAVI) for aortic stenosis (AS) became widespread, there arose the need for a Heart Team (HT) to choose the best treatment. There are few reports as regards its usefulness. Objectives: To analyze treatment outcomes in patients with AS evaluated by a HT for 10 years. Methods: Consecutive enrollment of all patients with AS who were candidates for TAVI between January 2012 and July 2021 to choose the best treatment, including surgical aortic valve replacement (SAVR) and conservative medical management (CMM). Results: Out of 841 patients, 455 were assigned to TAVI (53%), 213 to SAVR (24%), and 183 to CMM (23%). The percentage assigned to TAVI has increased from 48% to 62% over time (p <0.05). Patients who underwent TAVI versus those who underwent SAVR were older (86 ± 7 vs. 83 ± 7 years), had a higher EUROSCORE II (6.2, 95% CI 5.7-6.6 vs. 5.6; 95% CI 4.4-6.5) and were frailer (1.62 ± 1 vs. 0.91 ± 1) in all cases (p <0.01). Actuarial survival (95% CI) at 1 and 2 years was 88% (84-91%) and 82% (77-86%) for TAVI, 83% (76-88%) and 78% (70-84%) for SAVR, and 70% (60-87%) and 59% (48-68%) for CMM, respectively (p <0.001). Conclusions: For the first 10 years after a Heart Team was established for AS decision-making, approximately half of the patients were assigned to TAVI, and the rest were equally assigned in halves to either surgery or observation. Survival for patients who received interventions was similar at 2 years and higher than in those who did not.
- 1 December 2022
- Vol. 82 (6) , 904-913
Role of polypills in cardiovascular risk reduction in primary prevention
Unlike medications that contain fixed-dose combinations, such as those recommended by clinical guidelines for treating high blood pressure, the so-called polypills contain several drugs that simultaneously treat two or more cardiovascular conditions or risk factors. They were proposed 2 decades ago, both for primary and secondary prevention with the hypothesis that they could have wide dissemination and population penetration, improving the use of therapeutics with proven benefits individually, thanks to an increase in patient adherence by reducing the number of daily tablets and also by having an equal or lower cost.In this simple review, we present a look at risk stratification different from that posed by clinical scores and summarize the benefits of polypills in the treatment of risk factors and in the reduction of major cardiovascular events. Additionally, we review the clinical messages of the HOPE-3 trial, which aim to control two of the most prevalent conditions, such as high blood pressure and high cholesterol, through a combination of candesartan, hydrochlorothiazide and rosuvastatin. Finally, we propose its potential indication in a heterogeneous health system such as that of our country, both at the population level based on intermediate or low risk, determined intuitively or using a risk calculator, as well as in the personalized care that is practiced in many health scenarios.
- 1 December 2022
- Vol. 82 (6) , 904-913
Role of polypills in cardiovascular risk reduction in primary prevention
Unlike medications that contain fixed-dose combinations, such as those recommended by clinical guidelines for treating high blood pressure, the so-called polypills contain several drugs that simultaneously treat two or more cardiovascular conditions or risk factors. They were proposed 2 decades ago, both for primary and secondary prevention with the hypothesis that they could have wide dissemination and population penetration, improving the use of therapeutics with proven benefits individually, thanks to an increase in patient adherence by reducing the number of daily tablets and also by having an equal or lower cost.In this simple review, we present a look at risk stratification different from that posed by clinical scores and summarize the benefits of polypills in the treatment of risk factors and in the reduction of major cardiovascular events. Additionally, we review the clinical messages of the HOPE-3 trial, which aim to control two of the most prevalent conditions, such as high blood pressure and high cholesterol, through a combination of candesartan, hydrochlorothiazide and rosuvastatin. Finally, we propose its potential indication in a heterogeneous health system such as that of our country, both at the population level based on intermediate or low risk, determined intuitively or using a risk calculator, as well as in the personalized care that is practiced in many health scenarios.